CPA1 and venous thromboembolism: Based on general population recommendations, spironolactone doses of 25–100 mg daily appear to have low risks of adverse side effects, while high doses of CPA (≥10 mg) may lead to meningioma or venous thromboembolism, and flutamide and bicalutamide are associated with increased risks of liver toxicity.51